Search results for

Austria PATENT PROSECUTION Tier 1 Sonn & Partner Tier 2 Beer & Partner Kopecky & Schwarz Tier 3 Patentanwalt Dr Thomas M Haffner Patentanwälte Puchberger, Berger & Partner Patentanwälte Schütz und Partner Torggler & Hofinger Tier 4 Barger, Piso & Partner Patentanwaltskanzlei Wildhack & Jellinek

Plans to implement the European Patent Litigation Agreement - touted as the answer to Europe's patent dispute woes - are in trouble. Emma Barraclough looks at the cause of the impasse and asks what the European Commission will do next

The GPL has become the most common open source licence since its release in 1989. But only recently has a body of case law begun to develop on whether it is enforceable. James Gatto argues that cases in the US and Germany suggest that it is

Foreign IP owners used to think that China was reluctant to grant well-known mark status to their trade marks. They need to think again, says Huang Hui, as he explains how brand owners can use the rules to maximize their rights

Ensuring that expert witness evidence is used to maximum effect is crucial in IP litigation. Nick Gardner and Duncan Ribbons introduce a guide to the most effective way to marshal and deploy your expert evidence prepared by lawyers in seven jurisdictions

Emma Barraclough, London

On December 14 2006, the Court of First Instance (CFI) upheld that Community trade mark applications representing deer heads with the word "Venado" were confusingly similar to earlier trade marks consisting of a deer's head with a cross surrounded by a halo and the word "Jägermeister".

Acacia Technologies: an aggressive patent troll that feeds off the litigation fears of large corporations, or the champion of small technology companies who might not know how to go about enforcing their patents? Shahnaz Mahmud weighs up the evidence

Manufacturers of medicinal products are legally obliged to obtain regulatory approval for their product before marketing of that product may begin. However, where different salts, esters, ethers, isomers, complexes or derivatives of a brand (on-patent) drug are made by a generic company, and these differ significantly in properties with regard to safety and/or efficacy when compared to the patented drug, additional clinical data demonstrating the safety and/or efficacy of that generic drug must be submitted by the generic company to the marketing authority.

For brand managers looking to increase their product's profile and producers wanting to find new ways to finance movies and TV shows, product placement could be a win-win solution, says Brinsley Dresden, as he outlines negotiating tactics to help IP owners strike the deal they want